-
1
-
-
84923094635
-
-
National Cancer Institute. Bethesda, MD March 17
-
SEER Cancer Statistics Factsheets: Colon and Rectum Cancer. National Cancer Institute. Bethesda, MD, http:seer.cancer.govstatfactshtmlcolorect.html, March 17, 2014
-
(2014)
SEER Cancer Statistics Factsheets: Colon and Rectum Cancer
-
-
-
2
-
-
84880665721
-
Treatment of metastatic colon cancer: "The times they are A- changing."
-
PMID:23630214
-
Kemeny NE. Treatment of metastatic colon cancer: "the times they are A- changing." J Clin Oncol 2013;31:1913-6; PMID:23630214; http://dx.doi.org/10.1200/JCO.2013.49.4500
-
(2013)
J Clin Oncol
, vol.31
, pp. 1913-1916
-
-
Kemeny, N.E.1
-
3
-
-
84882455499
-
Long term survival after hepatic and pulmonary resection of the colorectal cancer metastases
-
PMID:23893480
-
Sourrouille I, Mordant P, Maggiori L, Dokmak S, Leseche G, Panis Y, Belghiti J, Castier Y. Long term survival after hepatic and pulmonary resection of the colorectal cancer metastases. J Surg Oncol 2013; 108:220-4; PMID:23893480; http://dx.doi.org/10.1002/jso.23385
-
(2013)
J Surg Oncol
, vol.108
, pp. 220-224
-
-
Sourrouille, I.1
Mordant, P.2
Maggiori, L.3
Dokmak, S.4
Leseche, G.5
Panis, Y.6
Belghiti, J.7
Castier, Y.8
-
4
-
-
67650136139
-
An MVA- based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases
-
PMID:18833005
-
Elkord E, Dangoor A, Drury NL, Harrop R, Burt DJ, Drijfhout JW, Hamer C, Andrews D, Naylor S, Sherlock D, et al. An MVA- based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother 2008; 31:820-9; PMID:18833005; http://dx.doi. org/10.1097/CJI.0b013e3181876ab3
-
(2008)
J Immunother
, vol.31
, pp. 820-829
-
-
Elkord, E.1
Dangoor, A.2
Drury, N.L.3
Harrop, R.4
Burt, D.J.5
Drijfhout, J.W.6
Hamer, C.7
Andrews, D.8
Naylor, S.9
Sherlock, D.10
-
5
-
-
84861645912
-
The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: A systematic review
-
PMID:22316439
-
Quan D, Gallinger S,Nhan C, AuerRA, Biagi JJ, Fletcher GG, Law CH, Moulton CA, Ruo L, Wei AC, Mcleod RS. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery 2012; 151:860-70; PMID:22316439; http://dx.doi.org/10.1016/j.surg.2011.12.018
-
(2012)
Surgery
, vol.151
, pp. 860-870
-
-
Quan, D.1
Gallinger, S.2
Nhan, C.3
Auer, R.A.4
Biagi, J.J.5
Fletcher, G.G.6
Law, C.H.7
Moulton, C.A.8
Ruo, L.9
Wei, A.C.10
Mcleod, R.S.11
-
6
-
-
77955066199
-
Sipuleucel-T immunotherapy for cas-tration-resistant prostate cancer
-
PMID:20818862
-
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for cas-tration-resistant prostate cancer. N Engl J Med 2010;363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
-
(2010)
N Engl J Med
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
Berger, E.R.4
Small, E.J.5
Penson, D.F.6
Redfern, C.H.7
Ferrari, A.C.8
Dreicer, R.9
Sims, R.B.10
-
7
-
-
79957831345
-
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma
-
PMID:21631324
-
Schwartzentruber DJ, Lawson DH, Richards JM, Contry RM, Miller DM, Terisman J, Gailani F, Riley L, Conlon K, Pockaj B, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364:2119-27; PMID:21631324; http://dx.doi.org/10.1056/NEJMoa1012863
-
(2011)
N Engl J Med
, vol.364
, pp. 2119-2127
-
-
Schwartzentruber, D.J.1
Lawson, D.H.2
Richards, J.M.3
Contry, R.M.4
Miller, D.M.5
Terisman, J.6
Gailani, F.7
Riley, L.8
Conlon, K.9
Pockaj, B.10
-
8
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
PMID:20525992
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
Gonzalez, R.7
Robert, C.8
Schadendorf, D.9
Hassel, J.C.10
-
9
-
-
84893073441
-
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: A phase II, single-arm trial
-
not203202014; PMID:24335700
-
Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, sin-gle-arm trial. Neuro Oncol 2014; 16:274-9. not203202014; PMID:24335700; http://dx.doi.org/10.1093/ neuonc/not203
-
(2014)
Neuro Oncol
, vol.16
, pp. 274-279
-
-
Bloch, O.1
Crane, C.A.2
Fuks, Y.3
Kaur, R.4
Aghi, M.K.5
Berger, M.S.6
Butowski, N.A.7
Chang, S.M.8
Clarke, J.L.9
McDermott, M.W.10
-
10
-
-
84891484180
-
Secreted heat shock protein gp96-Ig: Next-generation vaccines for cancer and infectious diseases
-
PMID:24254084
-
Strbo N, Garcia-Soto A, Schreiber TH, Podack ER. Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases. Immunol Res 2013; 57:311-25; PMID:24254084; http://dx.doi. org/10.1007/s12026-013-8468-x
-
(2013)
Immunol Res
, vol.57
, pp. 311-325
-
-
Strbo, N.1
Garcia-Soto, A.2
Schreiber, T.H.3
Podack, E.R.4
-
11
-
-
84879097715
-
REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin) in patients with advanced solid tumors
-
PMID:22886613
-
Morris DG, Feng X, DiFrancesco LM, Fonseca K, Forsyth PA, Paterson AH, Coffey MC, Thompson B. REO-001: a phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin) in patients with advanced solid tumors. Invest New Drugs 2013; 31:696-706; PMID:22886613; http://dx.doi. org/10.1007/s10637-012-9865-z
-
(2013)
Invest New Drugs
, vol.31
, pp. 696-706
-
-
Morris, D.G.1
Feng, X.2
DiFrancesco, L.M.3
Fonseca, K.4
Forsyth, P.A.5
Paterson, A.H.6
Coffey, M.C.7
Thompson, B.8
-
12
-
-
84903208336
-
PD-1 pathway inhibitors: Changing the landscape of cancer immunotherapy
-
PMID:24955707
-
Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control 2014; 21:231-37; PMID:24955707
-
(2014)
Cancer Control
, vol.21
, pp. 231-237
-
-
Dolan, D.E.1
Gupta, S.2
-
13
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev 2012; 12:251-64.
-
(2012)
Nat Rev
, vol.12
, pp. 251-264
-
-
Pardoll, D.M.1
-
14
-
-
84888237576
-
Identification of pre- and post-treatment markers, clinical, and laboratory parameters associated with outcome in renal cell cancer patients treated with MVA-5T4
-
PMID:23875174
-
Said R, mato RJ. Identification of pre- and post-treatment markers, clinical, and laboratory parameters associated with outcome in renal cell cancer patients treated with MVA-5T4. FrontOncol 2013; 3:185; PMID:23875174; http://dx.doi.org/10.3389/fonc.2013.00185
-
(2013)
FrontOncol
, vol.3
, pp. 185
-
-
Said, R.1
Mato, R.J.2
-
15
-
-
80053378780
-
Viral vector-based therapeutic cancer vaccines
-
Larocca C, chlom J. Viral vector-based therapeutic cancer vaccines. Cancer J 2011; 5:359-71; http://dx.doi. org/10.1097/PPO.0b013e3182325e63
-
(2011)
Cancer J
, vol.5
, pp. 359-371
-
-
Larocca, C.1
Chlom, J.2
-
16
-
-
78649369270
-
TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4- lessons learned and future development
-
PMID:20975327
-
Kim DW, Krishnamurthy V, Bines SB, Kaufman HL. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4- lessons learned and future development. Hum Vaccin 2010; 6:784-91; PMID:20975327; http://dx.doi.org/10.4161/hv.6.10.13144
-
(2010)
Hum Vaccin
, vol.6
, pp. 784-791
-
-
Kim, D.W.1
Krishnamurthy, V.2
Bines, S.B.3
Kaufman, H.L.4
-
17
-
-
33745223435
-
Vaccination of colorectal cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease Control: A phase III trial
-
PMID:16740766
-
Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, Myers KA, Drury N, Kingsman SM, Hawkins RE, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease Control: a phase III trial. Clin Cancer Res 2006; 12:3416-24; PMID:16740766; http://dx.doi.org/10.1158/1078-0432.CCR-05-2732
-
(2006)
Clin Cancer Res
, vol.12
, pp. 3416-3424
-
-
Harrop, R.1
Connolly, N.2
Redchenko, I.3
Valle, J.4
Saunders, M.5
Ryan, M.G.6
Myers, K.A.7
Drury, N.8
Kingsman, S.M.9
Hawkins, R.E.10
-
18
-
-
34547652648
-
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses
-
PMID:17671134
-
Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Melcher A, Nicholls J, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007; 13:4487-94; PMID:17671134; http://dx.doi.org/10.1158/1078-0432.CCR-07-0704
-
(2007)
Clin Cancer Res
, vol.13
, pp. 4487-4494
-
-
Harrop, R.1
Drury, N.2
Shingler, W.3
Chikoti, P.4
Redchenko, I.5
Carroll, M.W.6
Kingsman, S.M.7
Naylor, S.8
Melcher, A.9
Nicholls, J.10
-
19
-
-
42649138944
-
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin an irinotecan) is safe and induced potent immune responses
-
PMID:18060404
-
Harrop R, Noel Drury W, Shingler P, Chikoti I, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven N, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin an irinotecan) is safe and induced potent immune responses. Cancer Immunol Immunother 2008; 57:977-86; PMID:18060404; http://dx.doi.org/10.1007/s00262-007-0428-7
-
(2008)
Cancer Immunol Immunother
, vol.57
, pp. 977-986
-
-
Harrop, R.1
Noel Drury, W.2
Shingler, P.3
Chikoti, I.4
Redchenko, I.5
Carroll, M.W.6
Kingsman, S.M.7
Naylor, S.8
Griffiths, R.9
Steven, N.10
-
20
-
-
79151471986
-
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell-clear-cell carcinoma: Clinical and immunological findings
-
Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, et al. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell-clear-cell carcinoma: clinical and immunological findings. Cancer Immuno Immunother 2011; 60:261-71; http://dx.doi.org/10.1007/s00262-010-0935-9
-
(2011)
Cancer Immuno Immunother
, vol.60
, pp. 261-271
-
-
Oudard, S.1
Rixe, O.2
Beuselinck, B.3
Linassier, C.4
Banu, E.5
Machiels, J.P.6
Baudard, M.7
Ringeisen, F.8
Velu, T.9
Lefrere-Belda, M.A.10
-
21
-
-
67651173157
-
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure
-
PMID:18931824
-
Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, Limacher JM, Squiban P, Pantuck A. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 2009; 27:379-86; PMID:18931824; http://dx.doi.org/10.1007/s10637-008-9187-3
-
(2009)
Invest New Drugs
, vol.27
, pp. 379-386
-
-
Dreicer, R.1
Stadler, W.M.2
Ahmann, F.R.3
Whiteside, T.4
Bizouarne, N.5
Acres, B.6
Limacher, J.M.7
Squiban, P.8
Pantuck, A.9
-
22
-
-
50349090322
-
A phase II study of TG4010 (MVA-MUC1-IL1) in association with chemotherapy in patients with Stage IIIIV Non-Small Cell Lung cancer
-
PMID:18594319
-
Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, Krzakowski M, Hess D, Tartour E, Chenard MP, et al. A phase II study of TG4010 (MVA-MUC1-IL1) in association with chemotherapy in patients with Stage IIIIV Non-Small Cell Lung cancer. J Thorac Oncol 2008; 3:735-44; PMID:18594319; http://dx.doi.org/10.1097/JTO.0b013e31817c6b4f
-
(2008)
J Thorac Oncol
, vol.3
, pp. 735-744
-
-
Ramlau, R.1
Quoix, E.2
Rolski, J.3
Pless, M.4
Lena, H.5
Levy, E.6
Krzakowski, M.7
Hess, D.8
Tartour, E.9
Chenard, M.P.10
-
25
-
-
84898469589
-
The diagnostics of colorectal cancer
-
Swiderska M, Choroman̈ka B, Dabrowska E, Konarzewska-Duchnowska E, Choromańska K, Szczurko G, Mÿliwiec P, Dadan J, Ladny JR, Zwierz K. The diagnostics of colorectal cancer. Contemp Oncol 2014;18:1-6.
-
(2014)
Contemp Oncol
, vol.18
, pp. 1-6
-
-
Swiderska, M.1
Choroman̈ka, B.2
Dabrowska, E.3
Konarzewska-Duchnowska, E.4
Choromańska, K.5
Szczurko, G.6
Mÿliwiec, P.7
Dadan, J.8
Ladny, J.R.9
Zwierz, K.10
-
26
-
-
33846595479
-
ASCO 2006 Update of recommendations for the use of tumor markers in gastrointrestinal cancer
-
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr. ASCO 2006 Update of recommendations for the use of tumor markers in gastrointrestinal cancer. J Clin Oncol 2006; 33:5313-27.
-
(2006)
J Clin Oncol
, vol.33
, pp. 5313-5327
-
-
Locker, G.Y.1
Hamilton, S.2
Harris, J.3
Jessup, J.M.4
Kemeny, N.5
Macdonald, J.S.6
Somerfield, M.R.7
Hayes, D.F.8
Bast, R.C.9
-
27
-
-
84865552100
-
Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer
-
PMID:22918931
-
Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012; 23 (supplement 8): viii6-9; PMID:22918931
-
(2012)
Ann Oncol
, vol.23
, pp. viii6-viii9
-
-
Finn, O.J.1
-
28
-
-
18344375283
-
Immunotherapy and chemotherapy - A practical partnership
-
PMID:15864281
-
Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005;5:397-405; PMID:15864281
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 397-405
-
-
Lake, R.A.1
Robinson, B.W.2
-
29
-
-
67449085969
-
Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferonalpha
-
PMID:19342962
-
Hawkins RE, MacDermott C, Shablak A, Hamer C, Thistlethwaite F, DruryNL, Chikoti P, ShinglerW,Naylor S, Harrop R. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferonalpha. J Immunother 2009; 32:424-9; PMID:19342962; http://dx.doi.org/10.1097/CJI.0b013e31819d297e
-
(2009)
J Immunother
, vol.32
, pp. 424-429
-
-
Hawkins, R.E.1
MacDermott, C.2
Shablak, A.3
Hamer, C.4
Thistlethwaite, F.5
Drury, N.L.6
Chikoti, P.7
Shingler, W.8
Naylor, S.9
Harrop, R.10
-
30
-
-
68449100522
-
Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered with interferon-alpha (IFN-alpha): A phase 2 trial
-
PMID:19561532
-
Amato RJ, Shingler W, Goonewardena M, de Belin J, Naylor S, Jac J, Willis J, Saxena S, Hernandez-McClain J, Harrop R. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother 2009; 32:765-72; PMID:19561532; http://dx. doi.org/10.1097/CJI.0b013e3181ace876
-
(2009)
J Immunother
, vol.32
, pp. 765-772
-
-
Amato, R.J.1
Shingler, W.2
Goonewardena, M.3
De Belin, J.4
Naylor, S.5
Jac, J.6
Willis, J.7
Saxena, S.8
Hernandez-McClain, J.9
Harrop, R.10
-
31
-
-
58149354757
-
Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: A phase II trial
-
PMID:19010868
-
Amato RJ, Shingler W, Naylor S, Jac J, Willis J, Saxena S, Hernandez-McClain J, Harrop R. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin Cancer Res 2008; 14:7504-10; PMID:19010868; http://dx.doi. org/10.1158/1078-0432.CCR-08-0668
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7504-7510
-
-
Amato, R.J.1
Shingler, W.2
Naylor, S.3
Jac, J.4
Willis, J.5
Saxena, S.6
Hernandez-McClain, J.7
Harrop, R.8
-
32
-
-
60549106426
-
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
-
PMID:19128501
-
Kaufman H, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, et al. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med 2009; 7:2; PMID:19128501; http://dx.doi.org/10.1186/1479-5876-7-2
-
(2009)
J Transl Med
, vol.7
, pp. 2
-
-
Kaufman, H.1
Taback, B.2
Sherman, W.3
Kim, D.W.4
Shingler, W.H.5
Moroziewicz, D.6
DeRaffele, G.7
Mitcham, J.8
Carroll, M.W.9
Harrop, R.10
-
33
-
-
48549088424
-
Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): A phase 2 trial
-
PMID:18528296
-
Amato RJ, Drury N, Naylor S, Jac J, Saxena S, Cao A, Hernandez-McClain J,Harrop R. Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 2008; 31:577-85; PMID:18528296; http://dx.doi.org/10.1097/CJI.0b013e31817deafd
-
(2008)
J Immunother
, vol.31
, pp. 577-585
-
-
Amato, R.J.1
Drury, N.2
Naylor, S.3
Jac, J.4
Saxena, S.5
Cao, A.6
Hernandez-McClain, J.7
Harrop, R.8
-
35
-
-
15944410592
-
Inhibition of CD4 (C) 25 CT regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
-
PMID:15591121
-
Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4 (C) 25 CT regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105:2862-8; PMID:15591121; http://dx.doi.org/10.1182/blood-2004-06-2410
-
(2005)
Blood
, vol.105
, pp. 2862-2868
-
-
Lutsiak, M.E.1
Semnani, R.T.2
De Pascalis, R.3
Kashmiri, S.V.4
Schlom, J.5
Sabzevari, H.6
|